TXNIP inhibition in the treatment of type 2 diabetes mellitus: design, synthesis, and biological evaluation of quinazoline derivatives

Thioredoxin interacting protein (TXNIP) is a potential drug target for type 2 diabetes mellitus (T2DM) treatment. A series of quinazoline derivatives were designed, synthesised, and evaluated to inhibit TXNIP expression and protect from palmitate (PA)-induced β cell injury. In vitro cell viability a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Aiyun, Guan, Li, Su, Wanzhen, Zhao, Ning, Song, Xuwen, Wang, Jin, Tang, Xiaoxiao, Li, Weize, Jiao, Xiangying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858527/
https://www.ncbi.nlm.nih.gov/pubmed/36651294
http://dx.doi.org/10.1080/14756366.2023.2166937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858527/
https://www.ncbi.nlm.nih.gov/pubmed/36651294
http://dx.doi.org/10.1080/14756366.2023.2166937

Ejemplares similares